公开(公告)号：DE60127237T2

公开(公告)日：2007-12-20

申请号：DE60127237

申请日：2001-01-30

Applicant: IDEXX LAB INC

Inventor： LAWTON ROBERT L ,  AIYAPPA ASHOK P ,  LIU WENDY W ,  MERMER BRION ,  GUO HONGLIANG ,  KRAH EUGENE R

IPC: C07K16/42 ,  C12N15/09 ,  A61K9/08 ,  A61K39/395 ,  A61P37/08 ,  A61P43/00 ,  C12P21/08

Abstract: The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.

公开(公告)号：DE60127237D1

公开(公告)日：2007-04-26

申请号：DE60127237

申请日：2001-01-30

Applicant: IDEXX LAB INC

Inventor： LAWTON ROBERT L ,  AIYAPPA ASHOK P ,  LIU WENDY W ,  MERMER BRION ,  GUO HONGLIANG ,  KRAH EUGENE R

IPC: C07K16/42 ,  C12N15/09 ,  A61K9/08 ,  A61K39/395 ,  A61P37/08 ,  A61P43/00 ,  C12P21/08

Abstract: The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.

公开(公告)号：AU3310201A

公开(公告)日：2001-08-14

申请号：AU3310201

申请日：2001-01-30

Applicant: IDEXX LAB INC

Inventor： LAWTON ROBERT L ,  AIYAPPA ASHOK P ,  LIU WENDY W ,  MERMER BRION ,  GUO HONGLIANG ,  KRAH EUGENE R III

IPC: C12N15/09 ,  A61K9/08 ,  A61K39/395 ,  A61P37/08 ,  A61P43/00 ,  C07K16/42 ,  C12P21/08

Abstract: The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.